Côte d'Ivoire vs New Zealand: Prevalence rate of diabetes in adults
Côte d'Ivoire
6.9
in 2014
New Zealand
6.9
in 2014
Côte d'Ivoire rank
142nd
New Zealand rank
142nd
Prevalence rate of diabetes in adults over time
- Côte d'Ivoire
- New Zealand
How they compare
Côte d'Ivoire currently reports 6.9 against 6.9 in New Zealand, a difference of 0.
Across all 35 years both countries report, New Zealand has been ahead every year.
Côte d'Ivoire ranks 142nd and New Zealand ranks 142nd of 190 countries.
New Zealand has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Côte d'Ivoire | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.63 | 5.54 | 1.91 | New Zealand |
| 1990s | 4.68 | 6.1 | 1.42 | New Zealand |
| 2000s | 5.75 | 6.67 | 0.92 | New Zealand |
| 2010s | 6.62 | 6.84 | 0.22 | New Zealand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of diabetes in adults, Côte d'Ivoire or New Zealand?
- Côte d'Ivoire, at 6.9 against 6.9 in New Zealand as of 2014.
- What is the difference in prevalence rate of diabetes in adults between Côte d'Ivoire and New Zealand?
- 0, with Côte d'Ivoire ahead.
- How many years of comparable data are there for Côte d'Ivoire and New Zealand?
- 35 years are reported by both, from 1980 to 2014.
- How do Côte d'Ivoire and New Zealand rank globally for prevalence rate of diabetes in adults?
- Côte d'Ivoire ranks 142nd and New Zealand ranks 142nd of 190 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of diabetes in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of people with diabetes among those aged over 18, based on general population surveys and statistical modeling. Diabetes is a risk factor for chronic complications, including cardiovascular disease, and premature death.